Overview

A Phase 1 Study of the SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1 study of BBP-398, a SHP2 inhibitor, in combination with nivolumab, a PD-1 antibody, in patients with NSCLC with a KRAS mutation. The study involves 2 parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion.

Phase:

Phase 1

Details

Lead Sponsor:

Navire Pharma Inc., a BridgeBio company

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab